

to iatrogenic hypoxic medullary injury: avoidance of NSAIDs in patients on SGLT2 inhibitors and cessation of SGLT2 inhibitors prior to radiocontrast studies.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. All authors contributed equally to the generation of the hypotheses that formed the basis for this observation. S.N.H. wrote the manuscript with the participation and feedback of M.K., S.R., C.R., and Z.A. S.N.H. is the guarantor of this work and, as such, had full

access to all the data in the study and takes responsibility for the integrity and accuracy of the data analysis.

References

1. Wanner C, Inzucchi SE, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med* 2016;375:323–334
2. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), 2016. Available from

<http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm>. Accessed 14 July 2016

3. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. *Diabetologia* 2003;46:1153–1160
4. Heyman SN, Rosenberger C, Rosen S, Khamaisi M. Why is diabetes mellitus a risk factor for contrast-induced nephropathy? *BioMed Res Int* 2013;2013:123589
5. O'Neill J, Fasching A, Pihl L, Patinha D, Franzén S, Palm F. Acute SGLT inhibition normalizes O₂ tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. *Am J Physiol Renal Physiol* 2015;309:F227–F234